Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Paraneoplastic Syndromes

ClinicalTrials.gov lists 453 trials for Paraneoplastic Syndromes or a narrower condition beneath it. Alexion Pharmaceuticals, Inc. has the most among industry and government lead sponsors, with 20.

MeSH D010257 Neoplasms Neoplasm C04
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 45 Phase 1/2 Phase 1/2 12 Phase 2 Phase 2 63 Phase 2/3 Phase 2/3 14 Phase 3 Phase 3 84 Phase 4 Phase 4 14 Not applicable Not applicable 64 Observational Observational 149 Phase 1 Phase 1 45 Phase 1/2 Phase 1/2 12 Phase 2 Phase 2 63 Phase 2/3 Phase 2/3 14 Phase 3 Phase 3 84 Phase 4 Phase 4 14 Not applicable Not applicable 64 Observational Observational 149

Trials per phase

1 more section with rows

8 of the 453 trials are tagged with Paraneoplastic Syndromes itself; the rest are tagged with a narrower condition beneath it.

Get the Paraneoplastic Syndromes report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Paraneoplastic Syndromes trials start? (31)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 54

1991: 1 trials (Observational 1) 1993: 1 trials (Not applicable 1) 1994: 1 trials (Not applicable 1) 1995: 4 trials (Observational 2, Not applicable 1, Phase 3 1) 1997: 1 trials (Other 1) 2001: 2 trials (Phase 4 2) 2002: 3 trials (Observational 1, Phase 3 1, Phase 1 1) 2003: 2 trials (Phase 4 1, Phase 3 1) 2004: 4 trials (Phase 3 2, Phase 1/2 1, Phase 1 1) 2005: 4 trials (Other 1, Phase 2 2, Phase 1/2 1) 2006: 5 trials (Observational 1, Not applicable 1, Phase 3 3) 2007: 6 trials (Observational 1, Phase 4 1, Phase 3 2, Phase 2 2) 2008: 4 trials (Observational 1, Phase 2 3) 2009: 8 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 2, Phase 1 1) 2010: 6 trials (Observational 1, Not applicable 1, Phase 3 1, Phase 2 1, Phase 1 2) 2011: 10 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 3, Phase 2 3, Phase 1 1) 2012: 6 trials (Observational 2, Not applicable 1, Phase 3 1, Phase 2 1, Phase 1 1) 2013: 5 trials (Observational 3, Phase 3 2) 2014: 14 trials (Observational 5, Not applicable 1, Phase 3 4, Phase 2 4) 2015: 13 trials (Observational 3, Not applicable 2, Phase 3 2, Phase 2 6) 2016: 12 trials (Observational 3, Not applicable 3, Phase 3 2, Phase 2 2, Phase 1/2 1, Phase 1 1) 2017: 13 trials (Observational 8, Phase 2 2, Phase 1 3) 2018: 16 trials (Observational 3, Not applicable 3, Phase 4 2, Phase 3 5, Phase 2/3 1, Phase 2 2) 2019: 26 trials (Observational 10, Not applicable 3, Phase 3 7, Phase 2/3 1, Phase 2 4, Phase 1 1) 2020: 25 trials (Observational 13, Not applicable 1, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1 3) 2021: 28 trials (Observational 14, Not applicable 3, Phase 3 9, Phase 2/3 1, Phase 2 1) 2022: 34 trials (Observational 10, Not applicable 10, Phase 3 5, Phase 2/3 3, Phase 2 4, Phase 1/2 1, Phase 1 1) 2023: 34 trials (Observational 14, Not applicable 9, Phase 3 5, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 2) 2024: 54 trials (Observational 19, Not applicable 8, Phase 4 1, Phase 3 10, Phase 2/3 5, Phase 2 4, Phase 1/2 2, Phase 1 5) 2025: 45 trials (Observational 12, Not applicable 3, Phase 4 2, Phase 3 7, Phase 2/3 1, Phase 2 3, Phase 1/2 2, Phase 1 15)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 55
2025 45
2024 54
2023 34
2022 34
2021 28
2020 25
2019 26
2018 16
2017 13

Showing 10 of 31 earlier years.

Start your 14-day trial Email me all 31 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 67 trials starting in 2026 and about 54 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 76 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 201 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Paraneoplastic Syndromes trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 45
Phase 1/2 12
Phase 2 63
Phase 2/3 14
Phase 3 84
Phase 4 14
Not applicable 64
Observational 149
Expanded access 8

How many Paraneoplastic Syndromes trials are recruiting? (11)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 34
Recruiting 113
Enrolling by invitation 10
Active, not recruiting 30
Completed 172

Showing 5 of 11 statuses.

Start your 14-day trial Email me all 11 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Paraneoplastic Syndromes trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Alexion Pharmaceuticals, Inc. 20
argenx 17
UCB Biopharma SRL 14
Corcept Therapeutics 9
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 7

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Paraneoplastic Syndromes? (13)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Efgartigimod 16
3, 4-Diaminopyridine 13
RITUXIMAB 10
Rozanolixizumab 10
Zilucoplan 9

Showing 5 of 13 drugs.

Start your 14-day trial Email me all 13 drugs as a PDF

Interventions as named in the registry (2)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
IR Tacrolimus 4
Efgartigimod PH20 (ARGX-113) SC 4

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Paraneoplastic Syndromes trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Myasthenia gravis 170 23
Pneumonia 61 22
Myasthenia gravis crisis 52 16
Neuromyelitis optica spectrum disorder 49 3
COVID-19 35 13

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Paraneoplastic Syndromes? (53)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Ovarian Dermoid Cysts Associated with Paraneoplastic Syndrome N-methyl-D-aspartic Acid Receptor Antibodies Encephalitis. Journal of minimally invasive gynecology 2021 Yes
Axillary web syndrome among Chilean women with breast cancer: incidence and possible predisposing factors. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2020 Yes
Paraneoplastic Dermatoses: A Brief General Review and an Extensive Analysis of Paraneoplastic Pemphigus and Paraneoplastic Dermatomyositis. International journal of molecular sciences 2020 Yes
X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment. Endocrine reviews 2018 Yes
Cancer Cachexia: More Than Skeletal Muscle Wasting. Trends in cancer 2018 Yes

Showing 5 of 53 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages